Screener
Recursion Pharmaceuticals, Inc. RXRX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| (in thousands) | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued compensation | $17,962 | $31,771 |
| Accrued compute liabilities | 6,793 | 8,278 |
| Accrued development expenses | 4,298 | 2,693 |
| Accrued early discovery expenses | 4,621 | 4,581 |
| Accrued professional fees | 1,167 | 1,232 |
| Materials received not invoiced | 171 | 703 |
| Accrued taxes, other than income taxes | 3,557 | 3,912 |
| Unearned grants | 1,909 | — |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s accrued expenses?
- Recursion Pharmaceuticals, Inc. (RXRX) reported accrued expenses of $17.96M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s accrued expenses changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s accrued expenses decreased by 39.5% year-over-year, from $29.7M to $17.96M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s accrued expenses has grown at a 24.8% compound annual growth rate (CAGR), from $10.49M to $31.77M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Recursion Pharmaceuticals, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude